Horizons in Neuro-oncology is a series of talks and events to encourage collaboration and to increase the impact of research in neuro-oncology. The focus is on clinically applicable, or near-clinic, technologies and treatments that might improve patient outcomes, and in developing, supporting and implementing new treatments.
Although it is aimed at a clinical audience, it is open to all - health care professionals, students, researchers, charities, support groups, patients, carers and others.
Each session is typically 60 mins long, with a 40 - 45 minute talk, and then 15 min questions. All sessions are free to join and will be hosted online via Zoom. You are required to pre-register for each meeting in order to get the link. Recorded sessions will be made available afterwards on YouTube.
HIN sessions are organised and facilitated by our neuro-oncology Clinical Research Practitioner, Ms. Lillie Pakzad-Shahabi.
Organisational support is provided by the Computational Oncology Group at Imperial College London.
To register, please click on the Zoom link below the meeting details, which will take you to the registration page (you have to register for each talk individually - apologies).
All the times are GMT
Thursday 22nd Feb 2024 at 5 pm
Mr. Ranjeev Bhangoo (Consultant Neurosurgeon, Kings College Hospital)
Maximising tumour resection whilst preserving Quality of Life - the neurosurgeon's role and armamentarium in achieving an Oncofunctional balance
Mr Ranjeev Bhangoo is a Consultant Neurosurgeon and Clinical Director of Neuroscience at King's College Hospital London and The London Clinic. His subspeciality interest is neuro-oncology and he spent a year post training at the Institute Gustauve Rossy in Paris learning and developing new techniques for the treatment of Brain tumours. He is also the neurosurgeon to the European School of Oncology and the European Society of Therapeutic Radiation Oncology.
His talk will cover the use of techniques such as Brain Path minimally invasive neurosurgery, Navigated Transcranial Magnetic Stimulation and Laser Interstitial Thermal Therapy (LITT) to maximise tumour resection and consider surgery for the previously unresectable.
Tuesday 19th March 2024
Dr. Cressida Lorimer (Clinical Oncologist, Brighton)
The management of older and frailer patients with GBM – are we offering the right treatment to the right patient?
We recently completed the multicentre BRITER study, a prospective imaging study looking at using baseline MRI scans to predict changes in quality of life for older patients undergoing radiotherapy for newly diagnosed GBM. I will cover an overview of the evidence behind the treatment strategies for older and frailer patients with GBM, the increase in interest in the use of geriatric assessment techniques in this cohort and the results of the BRITER study.
Thursday 25th April 2024 at 5 pm
Dr. Raj Jena (Group Leader, University of Cambridge)
I am faking it - have I got your attention?
I have always found it fascinating that the brain, such a delicate structure, can tolerate such high doses of radiation with relatively little obvious adverse effects. However, digging under the surface, we know that our patients with brain tumours suffer a number of subtle neurocognitive deficits, from short term memory registration, and fatigue to task switching and holding attention. We are undertaking initial work to use synthetic MRI to build maps of white matter connectivity, and auto-segmentation algorithms to parse out the key processing areas of the brain - the so called 'attention networks'. We believe that this approach will give us a better ability to correlate radiation dose and neurocognitive outcomes for our patients.
Tuesday 28th May 2024
Prof. Michael Jenkinson (Liverpool)
Meningioma: The good, the bad and the ugly
Abstract to come
All talks are archived on YouTube
Thursday 25th Jan 2024 at 5 pm
Prof. Stefaan van Gool (Head of Translational Oncology, IOZK)
Multiphase combined treatment for GBM: update and expansion of patient data
We recently published the clinical evolution and survival data of 50 adults with GBM treated with individualized multimodal immunotherapy (IMI) as part of a multiphase combined treatment. We now expanded the patient group, and the period of follow-up (till November 2023) using the same patient definition.